Quanterix (QTRX) shareholder Kent Lake said Tuesday that it opposes the company's proposed deal with Akoya Biosciences (AKYA).
Kent Lake, which owns 7.25% of Quanterix's stock, argued the deal is bad for Quanterix shareholders as it values Akoya almost five times higher than Quanterix, despite Quanterix's "superior" growth and market opportunity.
Kent Lake said in its claims that Quanterix ended up bidding against itself for Akoya, as other potential buyers backed out. It also raised concerns about the Quanterix board, suggesting that some directors have conflicts of interest and have not acted in the best interests of shareholders.
Kent Lake urged Quanterix stockholders to vote against the proposed merger and also said it recently nominated three independent board candidates to represent shareholders' interests better.
Quanterix and Akoya Biosciences did not immediately reply to MT Newswires' request for comments.
QTRX shares were up 3.5% and AKYA shares were 5.2% higher in recent trading.
Price: 7.53, Change: +0.25, Percent Change: +3.43
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。